Broadfoot Jill M.'s Insider Trades & SAST Disclosures
Broadfoot Jill M.'s most recent trade in Atyr Pharma Inc was a trade of 3,750 Common Stock done . Disclosure was reported to the exchange on Feb. 3, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Broadfoot Jill M..To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Atyr Pharma Inc | Jill M. Broadfoot | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2025 | 3,750 | 33,017 (0%) | 0% | - | Common Stock | |
| Atyr Pharma Inc | Jill M. Broadfoot | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2025 | 3,750 | 3,750 | - | - | Restricted Stock Unit | |
| Atyr Pharma Inc | Jill M. Broadfoot | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 3.78 per share. | 03 Feb 2025 | 1,254 | 31,763 (0%) | 0% | 3.8 | 4,740 | Common Stock |
| Talphera Inc. | Jill M. Broadfoot | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2024 | 13,044 | 13,044 | - | - | Stock Option (Right to Buy) | |
| Talphera Inc. | Jill M. Broadfoot | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2024 | 2,174 | 4,280 (0%) | 0% | 0 | Common Stock | |
| Atyr Pharma Inc | Jill M. Broadfoot | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.79 per share. | 31 May 2024 | 5,000 | 27,960 (0%) | 0% | 1.8 | 8,950 | Common Stock |
| Atyr Pharma Inc | Jill M. Broadfoot | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2024 | 3,750 | 7,500 | - | - | Restricted Stock Unit | |
| Atyr Pharma Inc | Jill Broadfoot M. | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2024 | 3,750 | 22,411 (0%) | 0% | - | Common stock | |
| Atyr Pharma Inc | Broadfoot M. Jill | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.69 per share. | 05 Feb 2024 | 1,590 | 20,821 (0%) | 0% | 1.7 | 2,687 | Common stock |
| Atyr Pharma Inc | M. Jill Broadfoot | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 150,000 | 150,000 | - | - | Employee Stock Option (right to buy) | |
| Acelrx Pharmaceuticals Inc | Jill M. Broadfoot | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Oct 2023 | 3,487 | 3,487 | - | - | Stock Option (Right to Buy) | |
| Acelrx Pharmaceuticals Inc | Broadfoot Jill M. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Oct 2023 | 581 | 2,106 (0%) | 0% | 0 | Common Stock | |
| Atyr Pharma Inc | Jill M. Broadfoot | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 84,023 | 84,023 | - | - | Employee Stock Option (right to buy) | |
| Atyr Pharma Inc | Jill M. Broadfoot | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2023 | 3,750 | 11,250 | - | - | Restricted Stock Unit | |
| Atyr Pharma Inc | Jill M. Broadfoot | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2023 | 3,750 | 17,026 (0%) | 0% | - | Common stock | |
| Atyr Pharma Inc | Jill M. Broadfoot | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.36 per share. | 03 Feb 2023 | 1,566 | 15,460 (0%) | 0% | 2.4 | 3,696 | Common stock |
| Atyr Pharma Inc | Jill M. Broadfoot | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2022 | 75,347 | 75,347 | - | - | Employee Stock Option (right to buy) | |
| Atyr Pharma Inc | Jill M. Broadfoot | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2022 | 30,000 | 30,000 | - | - | Employee Stock Option (right to buy) | |
| Atyr Pharma Inc | Jill M. Broadfoot | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2022 | 15,000 | 15,000 | - | - | Restricted Stock Units | |
| Atyr Pharma Inc | Jill M. Broadfoot | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 6.75 per share. | 13 Jan 2022 | 1,923 | 12,112 (0%) | 0% | 6.7 | 12,980 | Common stock |
| Acelrx Pharmaceuticals Inc | Jill M. Broadfoot | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2021 | 30,000 | 30,000 | - | - | Stock Option (Right to Receive) | |
| Acelrx Pharmaceuticals Inc | Jill M. Broadfoot | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2021 | 15,000 | 15,000 (0%) | 0% | 0 | Common Stock | |
| Atyr Pharma Inc | Jill M. Broadfoot | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2021 | 54,000 | 54,000 | - | - | Employee Stock Option (Right to buy) | |
| Atyr Pharma Inc | Jill M. Broadfoot | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2021 | 892 | 0 | - | - | Restricted Stock Unit | |
| Atyr Pharma Inc | Jill M. Broadfoot | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2021 | 892 | 10,223 (0%) | 0% | - | Common stock | |
| Atyr Pharma Inc | Jill M. Broadfoot | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 7.66 per share. | 06 Feb 2021 | 390 | 9,833 (0%) | 0% | 7.7 | 2,987 | Common stock |
| Atyr Pharma Inc | Jill M. Broadfoot | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2021 | 50,000 | 50,000 | - | - | Employee Stock Option (right to buy) | |
| Atyr Pharma Inc | Jill M. Broadfoot | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 4.22 per share. | 19 Jun 2020 | 1,850 | 9,153 (0%) | 0% | 4.2 | 7,807 | Common Stock |
| Atyr Pharma Inc | Jill M. Broadfoot | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2020 | 30,000 | 30,000 | - | - | Employee Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges